Histological Risk Factors to Predict Clinical Relapse in Ulcerative Colitis With Endoscopically Normal Mucosa

Background and Aims The current goal of treatment for ulcerative colitis [UC] is endoscopic and ultimately histological mucosal healing. However, there is no consensus on the definition of histological mucosal healing. We evaluated histological risk factors for clinical relapse in UC patients with endoscopically normal mucosa to focus on the importance of histological evaluation. Methods Patients with UC who underwent colonoscopy confirming Mayo endoscopic subscore [MES] ≤ 1 with biopsies were enrolled into this retrospective cohort. Three expert pathologists evaluated the presence or absence of chronic inflammatory cell infiltrate, breaches in the surface epithelium, crypt abscesses, mucin depletion, crypt architectural irregularities and basal plasmacytosis. Clinical relapse was defined as partial Mayo score ≥ 3 or modification of induction treatment. Prediction models of clinical relapse were generated, especially in patients with MES 0. Results A total of 194 UC patients were enrolled. Histological abnormalities existed more frequently in patients with MES 1 than those with MES 0, while the vast majority of patients still possessed at least one abnormality. There was no significant difference in time to relapse between MES 0 and 1. Crypt architectural irregularities and mucin depletion were associated with time to relapse in patients with MES ≤ 1. In patients with MES 0, the presence of mucin depletion was the only factor significantly and independently associated with the risk of relapse (hazard ratio, 2.18 [1.16-5.82]; p = 0.03). Conclusions Mucin depletion was shown to be a histological risk factor for clinical relapse in UC patients with MES 0.

[1]  R. Pinho,et al.  Impact of Histological and Endoscopic Remissions on Clinical Recurrence and Recurrence-free Time in Ulcerative Colitis , 2017, Inflammatory bowel diseases.

[2]  D. Rubin,et al.  Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  L. Laine,et al.  Histological Disease Activity as a Predictor of Clinical Relapse Among Patients With Ulcerative Colitis: Systematic Review and Meta-Analysis , 2016, The American Journal of Gastroenterology.

[4]  P. Higgins,et al.  Endoscopic Mucosal Healing Predicts Favorable Clinical Outcomes in Inflammatory Bowel Disease: A Meta-analysis , 2016, Inflammatory bowel diseases.

[5]  G. Krolow,et al.  Aortic Occlusion in a Patient With Gastrointestinal Symptoms , 2016, The American Journal of Gastroenterology.

[6]  L. Stitt,et al.  Development and validation of a histological index for UC , 2015, Gut.

[7]  S. Travis,et al.  Development and validation of the Nancy histological index for UC , 2015, Gut.

[8]  B. Warren,et al.  Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up , 2015, Gut.

[9]  A. Bitton,et al.  Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. , 2015, Gastroenterology.

[10]  S. Travis,et al.  Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative. , 2014, Journal of Crohn's & colitis.

[11]  B. Korelitz,et al.  Histological healing favors lower risk of colon carcinoma in extensive ulcerative colitis. , 2014, World journal of gastroenterology.

[12]  M. Vandervoort,et al.  Histologic Evaluation of Ulcerative Colitis: A Systematic Review of Disease Activity Indices , 2014, Inflammatory bowel diseases.

[13]  D. Rubin,et al.  Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[14]  G. Petris,et al.  European consensus on the histopathology of inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[15]  A. Cheifetz,et al.  Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[16]  B. Flourié,et al.  Impact of mucosal healing on long‐term outcomes in ulcerative colitis treated with infliximab: a multicenter experience , 2013, Alimentary pharmacology & therapeutics.

[17]  P. Rutgeerts,et al.  Correlation Between the Endoscopic and Histologic Score in Assessing the Activity of Ulcerative Colitis , 2013, Inflammatory bowel diseases.

[18]  P. Rutgeerts,et al.  Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing , 2012, The American Journal of Gastroenterology.

[19]  R. D'Incà,et al.  Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: A prospective, multicenter study , 2012, Inflammatory bowel diseases.

[20]  E. Kuipers,et al.  Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation , 2011, Inflammatory bowel diseases.

[21]  Q Wang,et al.  Differentiation of colonic polyps by confocal laser endomicroscopy. , 2011, Endoscopy.

[22]  N. Harpaz,et al.  Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. , 2007, Gastroenterology.

[23]  M. Vatn,et al.  Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. , 2007, Gastroenterology.

[24]  Philippe Marteau,et al.  A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. , 2007, Gastroenterology.

[25]  A. Öst,et al.  A reproducible grading scale for histological assessment of inflammation in ulcerative colitis , 2000, Gut.

[26]  S. Riley,et al.  Microscopic activity in ulcerative colitis: what does it mean? , 1991, Gut.

[27]  R. Willén,et al.  Histologic and colonoscopic assessment of disease extension in ulcerative colitis. , 1987, Scandinavian journal of gastroenterology.

[28]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[29]  S. Truelove,et al.  Biopsy Studies in Ulcerative Colitis , 1956, British medical journal.

[30]  W. Sandborn Mucosal healing in inflammatory bowel disease. , 2008, Reviews in gastroenterological disorders.

[31]  A. Cohen,et al.  Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. , 2001, Gastroenterology.